Genomic alterations in the EGFR/HER2/HER3 pathway were present in 8/39 (20%) tumors: seven BTCs (2 EGFR amplification, three HER2 amplification, one HER2 mutation, one HER3 mutation), one esophageal (HER2 mutation), and one PDA had HER3 protein amplification by proteomic testing without HER3 gene amplification. This evidence concerns the gene EGFR and Patent ductus arteriosus.